Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 17/20 | 0.51 |
| ▸ | AKT1 | P31749 | 16/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11904466 | 0.93 | RPS6KB1 (0.52) | RPS6KB1AKT1MAPTCNR1NPSR1 | |
| SCHEMBL2063679 | 0.92 | RPS6KB1 (0.51) | RPS6KB1AKT1MAPTCNR1NPSR1 | |
| SCHEMBL2063243 | 0.91 | RPS6KB1 (0.49) | RPS6KB1AKT1MAPTCNR1NPSR1 | |
| SCHEMBL11904316 | 0.90 | RPS6KB1 (0.53) | RPS6KB1AKT1MAPTCNR1NPSR1 | |
| SCHEMBL11904621 | 0.89 | RPS6KB1 (0.63) | RPS6KB1AKT1 | |
| SCHEMBL2062977 | 0.89 | RPS6KB1 (0.51) | RPS6KB1AKT1 | |
| SCHEMBL11904260 | 0.89 | RPS6KB1 (0.60) | RPS6KB1AKT1 | |
| SCHEMBL2064139 | 0.86 | RPS6KB1 (0.46) | RPS6KB1AKT1MAPTCNR1NPSR1 | |
| SCHEMBL2064061 | 0.86 | GPR119 (0.44) | RPS6KB1AKT1MAPTCNR1NPSR1 | |
| SCHEMBL2064656 | 0.86 | GPR119 (0.47) | RPS6KB1AKT1MAPTCNR1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102216302-B | Akt and p70 s6 kinase inhibitors | LILLY CO ELI | 2013-08-21 | — | — | CN | disclosed |
| EP-2358710-B1 | AKT AND P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8148387-B2 | AKT and P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| CN-102216302-A | Akt and p70 s6 kinase inhibitors | LILLY CO ELI | 2011-10-12 | — | — | CN | disclosed |
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, MTOR | RPS6KB1 7/4885AKT1 17/4885MAPT 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.